DK2003969T3 - Mature dendritic cell compositions and methods for culturing same - Google Patents
Mature dendritic cell compositions and methods for culturing sameInfo
- Publication number
- DK2003969T3 DK2003969T3 DK07755113.3T DK07755113T DK2003969T3 DK 2003969 T3 DK2003969 T3 DK 2003969T3 DK 07755113 T DK07755113 T DK 07755113T DK 2003969 T3 DK2003969 T3 DK 2003969T3
- Authority
- DK
- Denmark
- Prior art keywords
- dendritic cells
- agonist
- signaling
- methods
- receptor
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 5
- 238000012258 culturing Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000011664 signaling Effects 0.000 abstract 3
- 108010029697 CD40 Ligand Proteins 0.000 abstract 2
- 101150013553 CD40 gene Proteins 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 108010085650 interferon gamma receptor Proteins 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 abstract 1
- 229940123189 CD40 agonist Drugs 0.000 abstract 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4238—Regulators of development
- A61K40/424—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/56—Kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/400,774 US8513008B2 (en) | 2004-10-07 | 2006-04-07 | Mature dendritic cell compositions and methods for culturing same |
| PCT/US2007/008734 WO2007117682A2 (en) | 2006-04-07 | 2007-04-06 | Mature dendritic cell compositions and methods for culturing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2003969T3 true DK2003969T3 (da) | 2011-09-12 |
Family
ID=38581685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07755113.3T DK2003969T3 (da) | 2006-04-07 | 2007-04-06 | Mature dendritic cell compositions and methods for culturing same |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8513008B2 (enExample) |
| EP (1) | EP2003969B1 (enExample) |
| JP (1) | JP5425618B2 (enExample) |
| KR (1) | KR101425686B1 (enExample) |
| CN (1) | CN101460054B (enExample) |
| AT (1) | ATE510451T1 (enExample) |
| AU (1) | AU2007235227B2 (enExample) |
| CA (1) | CA2648675C (enExample) |
| DK (1) | DK2003969T3 (enExample) |
| WO (1) | WO2007117682A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| KR101243577B1 (ko) | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
| JP5020935B2 (ja) | 2005-04-08 | 2012-09-05 | アルゴス セラピューティクス，インコーポレイティド | 樹状細胞組成物および方法 |
| ES2520026T3 (es) | 2006-09-18 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Composiciones y métodos para potenciar respuestas inmunitarias |
| WO2009039198A2 (en) * | 2007-09-17 | 2009-03-26 | The Trustees Of The University Of Pennsylvania | Generation of hyperstable mrnas |
| BRPI0818736A2 (pt) * | 2007-10-30 | 2017-06-13 | Univ Arkansas | composições e métodos para intensificar imunorrepostas à bactéria flagelada |
| CN101969990B (zh) | 2007-11-01 | 2014-07-09 | 阿肯色大学评议会 | 增强针对艾美球虫属的免疫反应的组合物和方法 |
| EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
| EP2254998B1 (en) * | 2008-02-28 | 2015-12-23 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| CN102811734B (zh) | 2010-01-21 | 2016-02-10 | 阿肯色大学评议会 | 增强免疫应答的疫苗载体和方法 |
| CN102971008B (zh) | 2010-06-09 | 2015-11-25 | 阿肯色大学评议会 | 降低弯曲菌属感染的疫苗和方法 |
| WO2012041635A1 (en) * | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
| CN109536446B (zh) * | 2012-02-10 | 2022-08-02 | 医疗法人社团博心厚生会 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
| US9603915B2 (en) | 2013-02-14 | 2017-03-28 | The Board of Trustees of the University of Akansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
| BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
| AU2015218865B2 (en) * | 2014-02-21 | 2021-06-10 | Coimmune, Inc. | TSCM cells and methods for use |
| EP3316897A4 (en) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
| JP2018535191A (ja) * | 2015-09-26 | 2018-11-29 | プライムヴァックス イミュノ−オンコロジー，インク． | 樹状細胞を産生するための組成物及び方法 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| WO2017123242A1 (en) * | 2016-01-15 | 2017-07-20 | Ding Enyu | A universal nucleic acid drug vector enhancing mrna stability and translatability |
| KR102767638B1 (ko) | 2016-05-03 | 2025-02-20 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
| JP2020500847A (ja) | 2016-11-16 | 2020-01-16 | プライムヴァックス イミュノ−オンコロジー，インク． | 癌の処置のための併用免疫療法 |
| CA3049225A1 (en) | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
| US11779599B2 (en) | 2017-11-07 | 2023-10-10 | Coimmune, Inc. | Methods and uses for dendritic cell therapy |
| CN111166876B (zh) * | 2018-11-13 | 2022-10-11 | 北京启辰生生物科技有限公司 | 一种免疫增强剂组合和编码核酸及其应用 |
| KR102698871B1 (ko) * | 2021-09-10 | 2024-08-28 | 이종균 | 수지상 세포, 자연 살해 세포 및 세포 독성 t 세포를 포함하는 암의 예방 또는 치료용 생물학적 조성물 |
| WO2024231621A1 (fr) * | 2023-05-05 | 2024-11-14 | Centre National De La Recherche Scientifique | Acide nucleique synthetique et ses utilisations therapeutiques |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0411228B1 (en) | 1989-07-31 | 1995-11-08 | International Business Machines Corporation | Controlled fiber-optic switch |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| CA2121798C (en) | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| KR100281264B1 (ko) | 1992-10-22 | 2001-02-01 | 마나배 게이사꾸 | 신규한 스핀고당 지질 및 그의 사용 |
| CN1045302C (zh) | 1993-04-15 | 1999-09-29 | 麒麟麦酒株式会社 | 新型(神经)鞘糖脂、含有它们的药物组合物及其用途 |
| PL181496B1 (pl) | 1996-03-20 | 2001-07-31 | Politechnika Slaska Im Wincent | Sposób wytwarzania ß-naftolu PL |
| AU705647B2 (en) | 1996-07-10 | 1999-05-27 | Immunex Corporation | Method of activating dendritic cells |
| US6017527A (en) | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
| TW555562B (en) | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
| ES2235324T3 (es) | 1997-04-10 | 2005-07-01 | Kirin Beer Kabushiki Kaisha | Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes. |
| TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
| ATE428769T1 (de) | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| CA2328604A1 (en) | 1998-05-26 | 1999-12-02 | Andrew Segal | Compositions and methods of modulating an immune response to an antigen |
| EP1185627A2 (en) | 1999-06-01 | 2002-03-13 | Cornell Research Foundation, Inc. | Activation of dendritic cells to enhance immunity |
| US20030077263A1 (en) | 1999-10-29 | 2003-04-24 | Immunex Corporation | Method of activating dendritic cells |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| ES2389645T3 (es) | 2000-06-19 | 2012-10-30 | Beth Israel Deaconess Medical Center | Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T |
| AU2001268564A1 (en) | 2000-06-22 | 2002-01-02 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US20040247563A1 (en) | 2000-11-02 | 2004-12-09 | Lynch David H. | Method of enhancing lymphocyte-mediated immune responses |
| AU2002224851A1 (en) | 2000-11-14 | 2002-05-27 | Universite Libre De Bruxelles | Generation and use of dendritic cells |
| JP2004520033A (ja) | 2001-01-15 | 2004-07-08 | イ・デ・エム・イミュノ−デジネ・モレキュル | 分化拘束された成熟樹状細胞の調製用補助組成物 |
| WO2002074345A2 (en) | 2001-03-16 | 2002-09-26 | Johns Hopkins University School Of Medicine | Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules |
| EP1270732A1 (en) | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| WO2003010301A1 (en) | 2001-07-25 | 2003-02-06 | I.D.M. Immuno-Designed Molecules | New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions |
| CA2453880A1 (en) | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| DK1437358T3 (da) | 2001-08-16 | 2007-02-05 | Daiichi Asubio Pharma Co Ltd | Hidtil ukendt glycolipid og medikament til autoimmune sygdomme indeholdende dette som det aktive stof |
| EP1444330A1 (en) | 2001-11-07 | 2004-08-11 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
| CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
| EP1572228A4 (en) | 2002-09-19 | 2009-03-04 | Centocor Inc | METHOD FOR THE INTRODUCTION OF THE TREATMENT OF DENDRITIC CELLS AND ITS USES |
| WO2004026318A1 (ja) | 2002-09-20 | 2004-04-01 | Kirin Beer Kabushiki Kaisha | α-グリコシルセラミドを有効成分とするＣ型肝炎ウイルス抑制剤 |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2004053095A2 (en) * | 2002-12-10 | 2004-06-24 | Merix Bioscience, Inc. | In situ maturation of dendritic cells |
| SE0301109D0 (sv) | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
| US20050003533A1 (en) | 2003-05-08 | 2005-01-06 | Pawel Kalinski | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |
| AU2004277376B2 (en) | 2003-07-18 | 2011-06-02 | Eastern Virginia Medical School | Apparatus for generating electrical pulses and methods of using the same |
| CN1882603A (zh) | 2003-11-25 | 2006-12-20 | 阿哥斯医疗公司 | mRNA转染的抗原呈递细胞 |
| US20050222048A1 (en) | 2004-03-31 | 2005-10-06 | The Research Foundation Of The City University Of New York | Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| KR101243577B1 (ko) | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| JP5020935B2 (ja) * | 2005-04-08 | 2012-09-05 | アルゴス セラピューティクス，インコーポレイティド | 樹状細胞組成物および方法 |
-
2006
- 2006-04-07 US US11/400,774 patent/US8513008B2/en not_active Expired - Fee Related
-
2007
- 2007-04-06 KR KR1020087024226A patent/KR101425686B1/ko not_active Expired - Fee Related
- 2007-04-06 WO PCT/US2007/008734 patent/WO2007117682A2/en not_active Ceased
- 2007-04-06 US US12/226,092 patent/US20120269832A1/en not_active Abandoned
- 2007-04-06 JP JP2009504346A patent/JP5425618B2/ja not_active Expired - Fee Related
- 2007-04-06 AT AT07755113T patent/ATE510451T1/de active
- 2007-04-06 DK DK07755113.3T patent/DK2003969T3/da active
- 2007-04-06 AU AU2007235227A patent/AU2007235227B2/en not_active Ceased
- 2007-04-06 CA CA2648675A patent/CA2648675C/en active Active
- 2007-04-06 CN CN200780020901.5A patent/CN101460054B/zh not_active Expired - Fee Related
- 2007-04-06 EP EP07755113A patent/EP2003969B1/en active Active
-
2013
- 2013-07-15 US US13/941,627 patent/US9523077B2/en not_active Expired - Fee Related
-
2016
- 2016-12-19 US US15/383,574 patent/US10184108B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5425618B2 (ja) | 2014-02-26 |
| JP2009533025A (ja) | 2009-09-17 |
| EP2003969A4 (en) | 2009-05-13 |
| CN101460054A (zh) | 2009-06-17 |
| CN101460054B (zh) | 2014-03-12 |
| KR20090006078A (ko) | 2009-01-14 |
| EP2003969A2 (en) | 2008-12-24 |
| ATE510451T1 (de) | 2011-06-15 |
| WO2007117682A2 (en) | 2007-10-18 |
| AU2007235227B2 (en) | 2012-10-04 |
| US20120269832A1 (en) | 2012-10-25 |
| CA2648675C (en) | 2015-03-10 |
| US20170096639A1 (en) | 2017-04-06 |
| US10184108B2 (en) | 2019-01-22 |
| US9523077B2 (en) | 2016-12-20 |
| AU2007235227A1 (en) | 2007-10-18 |
| US20140017788A1 (en) | 2014-01-16 |
| WO2007117682A3 (en) | 2008-10-16 |
| KR101425686B1 (ko) | 2014-08-01 |
| US8513008B2 (en) | 2013-08-20 |
| CA2648675A1 (en) | 2007-10-18 |
| US20070082400A1 (en) | 2007-04-12 |
| EP2003969B1 (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2003969T3 (da) | Mature dendritic cell compositions and methods for culturing same | |
| TW200630491A (en) | Mature dendritic cell compositions and methods for culturing same | |
| JP6788629B2 (ja) | 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法 | |
| KR102049928B1 (ko) | 효모-muc1 면역요법 조성물 및 그 용도 | |
| JP2009533025A5 (enExample) | ||
| IL187628A (en) | Method of culturing human embryonic stem cells into dendritic cells | |
| BRPI0212545A8 (pt) | método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t | |
| WO2009038760A3 (en) | Human gm-csf antigen binding proteins | |
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| BR112015021993A8 (pt) | polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular | |
| WO2017100338A4 (en) | Improved compositions and methods for viral delivery of neoepitopes and uses thereof | |
| Trepiakas et al. | Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function | |
| RU2020109423A (ru) | Способы и композиции для получения сурфактантного белка d (sp-d) | |
| Guang et al. | Research status of tumor-associated fibroblasts regulating immune cells | |
| CN102898528B (zh) | 钙网蛋白-可溶性程序性死亡受体1的融合蛋白及其制备方法和用途 | |
| Zhang et al. | Impact of connexin 43 coupling on survival and migration of multiple myeloma cells | |
| WO2005077048A3 (en) | Immune modulation by regulating expression of the “minor” gene in immune dendritic cells | |
| CA2510596A1 (en) | Dendritic cell line | |
| Lehner et al. | Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions | |
| EP4397682A3 (en) | Cell culture methods | |
| CN108251370A (zh) | 非细胞来源的多肽致敏的dc-cik细胞、其构建方法及应用 | |
| KR102052880B1 (ko) | 진세노사이드 Rg3를 유효성분으로 포함하는 차세대 수지상세포로의 성숙화 유도용 조성물 및 이를 이용한 차세대 수지상세포 제조방법 | |
| KR101270999B1 (ko) | 결핵균의 Ｒｖ２２９９ｃ 단백질을 이용한 수지상 세포의 성숙방법 | |
| AU2003217758A1 (en) | Cytokines and cytokine receptors with reduced immunogenicity | |
| KR20190093499A (ko) | 자연살해세포의 생산방법 |